Evaluation of the INNOVANCE PFA P2Y test cartridge: Sensitivity to P2Y₁₂ blockade and influence of anticoagulant

References

• Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001; 358: 527–533
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45: 1392–1396
   PubMed Web of Science ®Google Scholar
• Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303: 754–762
   PubMed Web of Science ®Google Scholar
• Erlinge D, Varenhorst C, Braun OO, James S, Winters KJ, Jakubowski JA, Brandt JT, Sugidachi A, Siegbahn A, Wallentin L. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008; 52: 1968–1977
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry U, Marcucci R, Blindt R, Angiolillo AL, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919–933
   PubMed Web of Science ®Google Scholar
• Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007; 25: 357–374
   PubMed Web of Science ®Google Scholar
• Niitsu Y, Jakubowski JA, Sugidachi A, Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 2005; 31: 184–194
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De SS, Murphy SA, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–2015
   PubMed Web of Science ®Google Scholar
• Shalito I, Kopyleva O, Serebruany V. Novel antiplatelet agents in development: Prasugrel, ticagrelor, and cangrelor and beyond. Am J Ther 2009; 16: 451–458
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–1057
   PubMed Web of Science ®Google Scholar
• Michelson AD. P2Y12 antagonism: Promises and challenges. Arterioscler Thromb Vasc Biol 2008; 28: s33–s38
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: The RESPOND study. Circulation 2010; 121: 1188–1199
   PubMed Web of Science ®Google Scholar
• Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, et al. Assessing the current role of platelet function testing. Clin Cardiol 2008; 31: I10–I16
   Google Scholar
• Michelson AD, Frelinger AL, III, Furman MI. Current options in platelet function testing. Am J Cardiol 2006; 98: 4N–10N
   PubMed Web of Science ®Google Scholar
• Harrison P, Frelinger AL, III, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007; 120: 323–336
   PubMed Web of Science ®Google Scholar
• Jilma B. Platelet function analyzer (PFA-100): A tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001; 138: 152–163
   PubMed Web of Science ®Google Scholar
• Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000; 83: 316–321
   PubMed Web of Science ®Google Scholar
• Chakroun T, Gerotziafas G, Robert F, Lecrubier C, Samama MM, Hatmi M, Elalamy I. In vitro aspirin resistance detected by PFA-100 closure time: Pivotal role of plasma von Willebrand factor. Br J Haematol 2004; 124: 80–85
   PubMed Web of Science ®Google Scholar
• Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002; 108: 37–42
   PubMed Web of Science ®Google Scholar
• Pidcock M, Harrison P. Can the PFA-100 be modified to detect P2Y12 inhibition?. J Thromb Haemost 2006; 4: 1424–1426
   PubMed Web of Science ®Google Scholar
• Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet function analyser (PFA-100) closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4: 1–8, Ref Type: Generic
   PubMedGoogle Scholar
• Jilma B. Synergistic antiplatelet effects of clopidogrel and aspirin detected with the PFA-100 in stroke patients. Stroke 2003; 34: 849–854
   PubMedGoogle Scholar
• Raman S, Jilma B. Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA-100. J Thromb Haemost 2004; 2: 2278–2279
   PubMed Web of Science ®Google Scholar
• Linnemann B, Schwonberg J, Rechner AR, Mani H, Lindhoff-Last E. Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y. Ann Hematol 2010; 89: 597–605
   PubMed Web of Science ®Google Scholar
• Koessler J, Kobsar AL, Rajkovic MS, Schafer A, Flierl U, Pfoertsch S, Bauersachs J, Steigerwald U, Rechner AR, Walter U. The new INNOVANCE PFA P2Y cartridge is sensitive to the detection of the P2Y12 receptor inhibition. Platelets 2010; 22: 19–25
   Google Scholar
• Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 85–92
   PubMed Web of Science ®Google Scholar
• Frelinger AL, III, Jakubowski JA, Li Y, Barnard MR, Fox ML, Linden MD, Sugidachi A, Winters KJ, Furman MI, Michelson AD. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thromb Haemost 2007; 98: 192–200
   PubMed Web of Science ®Google Scholar
• Frelinger AL, III, Jakubowski JA, Li Y, Barnard MR, Linden MD, Tarnow I, Fox ML, Sugidachi A, Winters KJ, Furman MI, et al. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. J Thromb Haemost 2008; 6: 359–365
   PubMed Web of Science ®Google Scholar
• Judge HM, Buckland RJ, Sugidachi A, Jakubowski JA, Storey RF. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thromb Haemost 2010; 103: 1210–1217
   PubMed Web of Science ®Google Scholar
• Bouman HJ, van Werkum JW, Breet NJ, ten CH, Hackeng CM, ten Berg JM. A case-control study on platelet reactivity in patients with coronary stent thrombosis. J Thromb Haemost 2011; 9: 906–916
   Google Scholar
• Chakroun T, Gerotziafas G, Robert F, Lecrubier C, Samama MM, Hatmi M, Elalamy I. In vitro aspirin resistance detected by PFA-100 closure time: Pivotal role of plasma von Willebrand factor. Br J Haematol 2004; 124: 80–85
   PubMed Web of Science ®Google Scholar
• Elsenberg EH, van Werkum JW, van de Wal RM, Zomer AC, Bouman HJ, Verheugt FW, Berg JM, Hackeng CM. The influence of clinical characteristics, laboratory and inflammatory markers on ‘high on-treatment platelet reactivity’ as measured with different platelet function tests. Thromb Haemost 2009; 102: 719–727
   PubMed Web of Science ®Google Scholar
• Kalb ML, Potura L, Scharbert G, Kozek-Langenecker SA. The effect of ex-vivo anticoagulants on whole blood platelet aggregation. Platelets 2009; 20: 7–11
   PubMed Web of Science ®Google Scholar
• Johnson A, Dovlatova N, Heptinstall S. Multiple electrode aggregometry and P2Y(12) antagonists. Thromb Haemost 2008; 99: 1127–1129
   PubMed Web of Science ®Google Scholar
• Bouman HJ, van Werkum JW, Hackeng CM, Verheugt FW, ten Berg JM. The importance of anticoagulant agents in measuring platelet aggregation in patients treated with clopidogrel and aspirin. J Thromb Haemost 2008; 6: 1040–1042
   PubMed Web of Science ®Google Scholar
• Pittens CA, Bouman HJ, van Werkum JW, ten Berg JM, Hackeng CM. Comparison between hirudin and citrate in monitoring the inhibitory effects of P2Y12 receptor antagonists with different platelet function tests. J Thromb Haemost 2009; 7: 1929–1932
   PubMed Web of Science ®Google Scholar
• Spiel AO, Mayr FB, Ladani N, Wagner PGSRG, Gilbert JC, Jilma B. The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction. Platelets 2009; 20: 334–340
   PubMed Web of Science ®Google Scholar
• Mayr FB, Kobl P, Jilma B, Siller-Matula J, Wagner PGSRG, Gilbert JC, Jilma-Stohlawetz P. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Transfusion 2010; 50: 1079–1087
   PubMed Web of Science ®Google Scholar
• Johnson A, Iyu D, Glenn J, Fox S, Sugidachi A, Jakubowski J, Heptinstall S. Assessment of the inhibitory effects of P2Y12 antagonists in vitro – the nature of the anticoagulant can influence the results obtained. Platelets 2010; 21: 405, (abstract p. 52)
   Google Scholar